Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to any ovary‐stimulating drugs for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to any ovary‐stimulating drugs for subfertility changes endometrial cancer compared with general population and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to clomiphene citrate for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to clomiphene citrate for subfertility changes endometrial cancer compared with general population and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to gonadotropins for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to gonadotropins for subfertility changes endometrial cancer compared with general population and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to clomiphene citrate and gonadotropins for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to clomiphene citrate and gonadotropins for subfertility changes endometrial cancer compared with general population and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to GnRH analogues for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
Endometrial carcinoma‐related death · women with stage I endometrial cancer
Summary of findings: EBRT showed no clear difference in endometrial carcinoma‐related death compared with no EBRT (moderate certainty).
1 finding from 1 review
HR 0.96 [0.72, 1.28]
2965 participants
Moderate
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Tumour response rate Defined as number of complete responses (i.e. disappearance of active Hodgkin lymphoma (gallium negative, ≥ 70% decrease in the sum of the products of the perpendicular diameters of measurable lesions, and negative bone marrow... · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete responses (i.e.… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Endometrial cancer risk (5 studies) · adults (aged at least 18 years)
Highest may leads to lower endometrial cancer risk (5 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.77 [0.65, 0.91]
60416 participants
Low
Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review